SQURPHARMA: Buy Confirmation of Chairman23 Feb 2026
Mr. Samuel S Chowdhury, Chairman of the Company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 20.01.2026.
SQURPHARMA: Buy Confirmation of Managing Director05 Feb 2026
Mr. Tapan Chowdhury, Managing Director of the company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 5.01.2026.
SQURPHARMA: Buy Confirmation of a Director05 Feb 2026
Mrs. Ratna Patra, one of the Directors of the Company, has further informed that she has completed her buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 15.01.2026.
SQURPHARMA: Q2 Financials01 Feb 2026
(Q2 Un-audited): Consolidated EPS was Tk. 8.20 for October-December 2025 as against Tk. 7.45 for October-December 2024; Consolidated EPS was Tk. 16.56 for July-December 2025 as against Tk. 14.32 for July-December 2024. Consolidated NOCFPS was Tk. 13.16 for July-December 2025 as against Tk. 8.28 for July-December 2024. Consolidated NAV per share was Tk. 162.41 as on December 31, 2025 and Tk. 157.88 as on June 30, 2025. (cont.)
SQURPHARMA: Board Meeting schedule under LR 16(1)25 Jan 2026
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
SQURPHARMA: Dividend Disbursement21 Jan 2026
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
SQURPHARMA: Buy Declaration of Chairman20 Jan 2026
Mr. Samuel S Chowdhury, Chairman of the Company, has expressed his intention to buy 20,00,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
SQURPHARMA: Buy Declaration of a Director15 Jan 2026
Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 10,00,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
SQURPHARMA: Buy Declaration of Managing Director05 Jan 2026
Mr. Tapan Chowdhury, Managing Director of the company, has expressed his intention to buy 20,00,000 shares of the company at prevailing market price (in the Public/Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
SQURPHARMA: Credit Rating Result14 Dec 2025
Credit Rating Information and Services PLC (CRISL) has assigned the rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook in consideration of its audited financials up to June 30, 2025; unaudited financials up to September 30, 2025 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
SQURPHARMA: Resumption after Record Date16 Nov 2025
Trading of the shares of the company will resume on 17.11.2025.
SQURPHARMA: Q1 Financials13 Nov 2025
(Q1 Un-audited): Consolidated EPS was Tk. 8.35 for July-September 2025 as against Tk. 6.87 for July-September 2024; Consolidated NOCFPS was Tk. 7.55 for July-September 2025 as against Tk. 3.89 for July-September 2024. Consolidated NAV per share was Tk. 167.50 as on September 30, 2025 and Tk. 157.88 as on June 30, 2025.
SQURPHARMA: Suspension for Record Date13 Nov 2025
Trading of the shares of the company will remain suspended on record date i.e., 16.11.2025.
SQURPHARMA: Spot News11 Nov 2025
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 12.11.2025 to 13.11.2025 and trading of the shares will remain suspended on record date i.e., 16.11.2025.
SQURPHARMA: Board Meeting schedule under LR 16(1)06 Nov 2025
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
SQURPHARMA: Dividend Declaration and Others23 Oct 2025
The Board of Directors has recommended 120% Cash Dividend for the year ended June 30, 2025. Date of AGM: 15.12.2025, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 16.11.2025. The Company has also reported Consolidated EPS of Tk. 27.04, Consolidated NAV per share of Tk. 157.88 and Consolidated NOCFPS of Tk. 19.52 for the year ended June 30, 2025 as against Tk. 23.61, Tk. 142.05 and Tk. 20.90 respectively for the year ended June 30, 2024. (cont.)
SQURPHARMA: Price Limit Open23 Oct 2025
There will be no price limit on the trading of the shares of the Company today (23.10.2025) following its corporate declaration.
SQURPHARMA: Board Meeting schedule under LR 19(1)12 Oct 2025
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 22, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
SQURPHARMA: Q3 Financials30 Apr 2025
(Q3 Un-audited): Consolidated EPS was Tk. 6.83 for January-March 2025 as against Tk. 5.55 for January-March 2024; Consolidated EPS was Tk. 21.15 for July 2024-March 2025 as against Tk. 18.24 for July 2023-March 2024. Consolidated NOCFPS was Tk. 11.90 for July 2024-March 2025 as against Tk. 17.32 for July 2023-March 2024. Consolidated NAV per share was Tk. 151.94 as on March 31, 2025 and Tk. 142.05 as on June 30, 2024. (cont.)
SQURPHARMA: Board Meeting schedule under LR 16(1)22 Apr 2025
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.